Dr Amit Kumar

SENIOR CONSULTANT Medical and Haemato Oncology , Cancer Institute

Patna

Meet the Doctor

About

Dr. Amit Kumar works as a Senior Consultant in Medical and Hemato Oncology at Jay Prabha Medanta Super Speciality Hospital in Patna. He received his MBBS from PMCH in Patna and his MD (General Medicine) from the Institute of Medic al Scienc es ,BHU in Varanasi. He obtained DNB (Medical Onc ology) and DM (Medic al Oncology) degrees from Tata Memorial Hospital in Mumbai. He also earned an MRCP SCE (Medical Oncology) and is an European  Certified Medical Oncologist. He is an expert in chemotherapy, immunotherapy,targeted therapy  and   bone marrow / stem cell transplantation. He practices both solid malignancies (Head and Neck, Lung, Breast, GI, GU, Gynaecological cancers and bone and soft tissue   sarcomas)  and haematolymphoid malignancies ( leukemia, lymphoma and myeloma). His special interest is in Geriatric Oncology and Rare tumours diagnosis and management. He has also been awarded the Gold Medal in MD (General Medicine).

Medical Qualifications

QUALIFICATIONSINSTITUTE / DEPARTMENTYEAR
MRCP SCE (Medical Oncology)UK2021
ECMOUK2021
DNB (Medical Oncology)TMH Mumbai2020
DM (Medical Oncology)TMH, Mumbai 2019
MD (General Medicine)IMS  BHU, Varanasi 2013
MBBS, PMCHPatna2006

Specialization and Expertise

  • Solid organ cancers
  • Blood cancers
  • Bone Marrow Transplant
  • Chemotherapy ,  immunotherapy and Precision medicine

Memberships & Certifications

  • ASCO 
  • ESMO
  • ISMPO
  • IMA

Awards & Accomplishments

  • GOLD MEDAL IN MD (GENERAL MEDICINE)
  • Presentation at ESMO, ASIA, Singapore

Publications

  •  Kumar A, Noronha N, Patil VM, Joshi A, Menon N, Kapoor A, Kumar R, Mahajan A, Janu A, Shetty O,  Prabhash K.   Efficacy and safety of Lorlatinib in subsequent lines of therapy in ALK and ROS 1 positive lung cancer. ESMO ASIA 2020 Nov. Annals of Oncology (2020) 31 (suppl_6): S1386-S1406. 10.1016/annonc/annonc367 :   Efficacy and safety of Lorlatinib in subsequent lines of therapy in ALK,
  • Kumar A, Noronha N, Patil VM, Joshi A, Menon N, Kapoor A,Prabhash K. Efficacy and safety of low dose immunotherapy in palliative settings of advanced solid tumours. ESMO 2020 Sep. DOI: 10.1016/annonc/annonc279 :   Efficacy and safety of low dose immunotherapy in palliative settings of advanced solid tumours.,
  • Amit Kumar, Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Nandini Sharrel Menon, and Kumar Prabhash. Long-term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy. Journal of Clinical Oncology 2020 38:15_suppl, e18507-e18507 :   Journal of Clinical Oncology,
  • Kumar A, Pramanik R, Raj S, Ahmed A, Kumar L. Acute Kidney Injury in Newly Diagnosed Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy: Experience of a Tertiary Cancer in India. Annals of Oncology (2017) 28 (suppl_10): x94-x99. 10.1093/annonc/mdx664(Impact factor-14.196) :   Experience of a Tertiary Cancer in India. Annals of Oncology,
  • Ramaswamy A, Nayak L, Roy Moulik N, Sengar M, Chinnaswamy G, Jobanputra K, Shah MJ, Kapoor A, Joshi A, Kumar A, Gokarn A, Bonda A, Cheriyalinkal Parambil B, Prasad M, Bagal B, Dhamne C, Narula G, Jain H, Ghosh J, Thorat J, Bajpai J, Menon N, Khattry N, Bhargava P, Punatar S, Gulia S, Banavali S, Gupta S, Srinivas S, Rath S, Vora T, Noronha V, Patil VM, Ostwal V, Prabhash K. COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Med. 2020 Dec;9(23):8747-8753. doi: 10.1002/cam4.3423. Epub 2020 Oct 31. PMID: 33128509; PMCID: PMC7724305. :   Outcomes from LMIC scenario with an emphasis on need for active treatment.,
  • Patil V, Noronha V, Dhumal SB, Joshi A, Menon N, Bhattacharjee A, Kulkarni S, Ankathi SK, Mahajan A, Sable N, Nawale K, Bhelekar A, Mukadam S, Chandrasekharan A, Das S, Vallathol D, D'Souza H, Kumar A, Agrawal A, Khaddar S, Rathnasamy N, Shenoy R, Kashyap L, Rai RK, Abraham G, Saha S, Majumdar S, Karuvandan N, Simha V, Babu V, Elamarthi P, Rajpurohit A, Kumar KAP, Srikanth A, Ravind R, Banavali S, Prabhash K. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health. 2020 Sep;8(9):e1213-e1222. doi: 10.1016/S2214-109X(20)30275-8. PMID: 32827483. :   an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health,
  • Kothari R, Ostwal V, Ramaswamy A, Gupta T, Bairwa S, Kapoor A, Kumar A, et al. Early survival outcomes in stage I-III operated colon cancer patients from a low prevalence, lower-middle income country: The Indian experience. Journal of ClinicalOncology 2018 36:4_suppl, 857-857 . https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.857 (Impact factor-26.303) :   The Indian experience. Journal of ClinicalOncology,
  • Ramaswamy A, Kothari R, Desouza A, Gupta T, Bairwa A, Kapoor A, Kumar A ,et al. Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX. South Asian J Cancer 2019Jul-Sep;8(3):160. https://dx.doi.org/10.4103%2Fsajc.sajc_176_18. https://www.ncbi.nlm.nih.gov/pubmed/31489288 (Impact Factor-0.8) :   prevalence country with predominant use of modified CAPOX,
  •  Kapoor A, Kumar A. Head and neck dermatofibrosarcoma protuberans: Scooping out data even in derth of evidence. Cancer Res Stat Treat2019;XX:XX:XX :   Scooping out data even in derth of evidence. Cancer Res Stat Treat,
  • Shetty D, Talker E, Mohanty P, Jain H, Yadav A, Jain H, Nayak L, Tembare P, Patkar N, Subramanian  P, & Kumar A . Clinical, hematological and cytogenetic profile in fibroblast growth factor receptor 1 rearranged hematolymphoid malignancies. International Journal of Research in Medical Sciences 2020.  8(4), 1556-1563. doi:http://dx.doi.org/10.18203/2320-6012.ijrms20201359 :   International Journal of Research in Medical Sciences 2020.  8(4), 1556-1563,
  • Kapoor A, Noronha V, Shetty O, Chougule A, Chandrani P, Patil VM, Menon N, Joshi A, Kumar R, Gurav M, Kumar A, Prabhash K. Molecular tumor board: Case 2 – Evolution of resistance in anaplastic lymphoma kinase driven non-small-cell lung carcinoma. Cancer Res Stat Treat 2020;3:89-92 :   Evolution of resistance in anaplastic lymphoma kinase driven non-small-cell lung carcinoma,
  • Kapoor A, Noronha V, Shetty OA, Kashyap L, Kumar A, Chandrani P, Patil VM, Joshi A, Menon N, Kumar R, Pragya R, Prabhash K. Concurrent EGFR and PIK3CA mutations in non-small-cell lung cancer. Cancer Res Stat Treat 2021;4:541-6 :   Concurrent EGFR and PIK3CA mutations in non-small-cell lung cancer,
  • Patil VM, Noronha V, Joshi A, Kumar A, Dsouza H, Bhattacharjee A, Mahajan A, Sabale N, Ghosh-Laskar S, Prabhash K. Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality! South Asian J Cancer. 2020 Oct;9(4):195-198. doi: 10.1055/s-0041-1728225. Epub 2021 Jun 12. PMID: 34131571; PMCID: PMC8197656. :   A Myth or Reality! South Asian J Cancer,
  •  Joshi Amit, Patil Vijay Maruti, Noronha Vanita, Bhattacharjee Atanu, Menon Nandini, Kumar Amit, Jain Parmanand, Mukadam Sadaf, Shrinivas Avadhoot, Punia Anjali, Abhyankar Anuja, Agarwal Amit, Khaddar Satvik, Rajpurohit Anu, Kumar Kanteti Aditya Pavan, Ravind Rahul, Das Kishore, Talreja Vikas, Dhumal Sachin, Prabhash Kumar (2021) Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study ecancer 15 1318. https://doi.org/10.3332/ecancer.2021.1318 :   Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation,
  • Bhargava PG, Kumar A, Simha V, Shah M, Patkar S, Goel M, Ostwal V, Ramaswamy A. Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas-A Relatively Rare Component of Biliary Tract Cancers in India. South Asian J Cancer. 2020 Oct;9(4):209-212. doi: 10.1055/s-0041-1726140. Epub 2021 Jun 12. PMID: 34268260; PMCID: PMC8276750. :   A Relatively Rare Component of Biliary Tract Cancers in India,
Meet this Doctor
Find another Doctor
Feedback